Jih‐Hsiang Lee

1.5k total citations
37 papers, 1.0k citations indexed

About

Jih‐Hsiang Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jih‐Hsiang Lee has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Jih‐Hsiang Lee's work include Lung Cancer Treatments and Mutations (22 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (11 papers). Jih‐Hsiang Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (11 papers). Jih‐Hsiang Lee collaborates with scholars based in Taiwan, United States and Netherlands. Jih‐Hsiang Lee's co-authors include James Chih‐Hsin Yang, Chia‐Chi Lin, Bin-Chi Liao, Jin‐Yuan Shih, Chong‐Jen Yu, Chao‐Chi Ho, Giuseppe Giaccone, Johannes Voortman, Yisong Wang and Kuan‐Yu Chen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jih‐Hsiang Lee

35 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jih‐Hsiang Lee Taiwan 19 669 561 347 196 98 37 1.0k
Sara Baglivo Italy 17 661 1.0× 541 1.0× 306 0.9× 187 1.0× 58 0.6× 39 993
Shinnosuke Ikemura Japan 18 485 0.7× 487 0.9× 494 1.4× 233 1.2× 44 0.4× 46 959
Assunta Sgambato Italy 15 441 0.7× 416 0.7× 293 0.8× 125 0.6× 57 0.6× 31 742
Ken Uchibori Japan 15 567 0.8× 614 1.1× 360 1.0× 156 0.8× 36 0.4× 59 885
Giuseppina Rosaria Rita Ricciardi Italy 16 588 0.9× 483 0.9× 313 0.9× 293 1.5× 30 0.3× 42 947
Pietro De Placido Italy 13 488 0.7× 396 0.7× 245 0.7× 225 1.1× 60 0.6× 53 816
Toshio Fujino Japan 16 420 0.6× 563 1.0× 402 1.2× 142 0.7× 58 0.6× 54 975
Naixin Liang China 14 523 0.8× 437 0.8× 248 0.7× 214 1.1× 47 0.5× 34 906
Akihiko Miyanaga Japan 18 446 0.7× 426 0.8× 638 1.8× 295 1.5× 74 0.8× 75 1.1k

Countries citing papers authored by Jih‐Hsiang Lee

Since Specialization
Citations

This map shows the geographic impact of Jih‐Hsiang Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jih‐Hsiang Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jih‐Hsiang Lee more than expected).

Fields of papers citing papers by Jih‐Hsiang Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jih‐Hsiang Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jih‐Hsiang Lee. The network helps show where Jih‐Hsiang Lee may publish in the future.

Co-authorship network of co-authors of Jih‐Hsiang Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Jih‐Hsiang Lee. A scholar is included among the top collaborators of Jih‐Hsiang Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jih‐Hsiang Lee. Jih‐Hsiang Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lee, Jih‐Hsiang, et al.. (2022). Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors. JTO Clinical and Research Reports. 3(11). 100405–100405. 6 indexed citations
3.
4.
Lee, Jih‐Hsiang, Tom Wei‐Wu Chen, Chih‐Hung Hsu, et al.. (2019). A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Investigational New Drugs. 38(1). 99–110. 52 indexed citations
5.
Wu, Tinghui, Emily Han-Chung Hsiue, Jih‐Hsiang Lee, et al.. (2018). Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients. Clinical Lung Cancer. 19(3). e361–e372. 19 indexed citations
6.
Wu, Tinghui, Emily Han-Chung Hsiue, Jih‐Hsiang Lee, & James Chih‐Hsin Yang. (2017). MA08.05 Depth of Response to First-Line EGFR TKI Does Not Predict Survival in EGFR-Mutated NSCLC Patients. Journal of Thoracic Oncology. 12(1). S386–S387. 2 indexed citations
7.
Liao, Bin-Chi, Jih‐Hsiang Lee, Chia‐Chi Lin, et al.. (2017). Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. Journal of the Formosan Medical Association. 117(4). 326–331. 11 indexed citations
8.
Liao, Bin-Chi, Chia‐Chi Lin, Jih‐Hsiang Lee, & James Chih‐Hsin Yang. (2017). Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 110. 7–13. 38 indexed citations
9.
Hsiue, Emily Han-Chung, Jih‐Hsiang Lee, Chia‐Chi Lin, & James Chih‐Hsin Yang. (2016). Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Review of Molecular Diagnostics. 16(12). 1251–1257. 18 indexed citations
10.
Liao, Bin-Chi, Chia‐Chi Lin, Jih‐Hsiang Lee, & James Chih‐Hsin Yang. (2016). Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Biomedical Science. 23(1). 86–86. 41 indexed citations
11.
Liao, Bin-Chi, Jih‐Hsiang Lee, Chia‐Chi Lin, et al.. (2015). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology. 10(12). 1754–1761. 138 indexed citations
12.
Lin, Ching‐Hung, Chen‐Yang Shen, Jih‐Hsiang Lee, et al.. (2015). High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. PLoS ONE. 10(4). e0124908–e0124908. 9 indexed citations
13.
Thomas, Anish, Jih‐Hsiang Lee, Zied Abdullaev, et al.. (2014). Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(4). 567–571. 26 indexed citations
14.
Lee, Jih‐Hsiang, Yulin Lin, Wei‐Hsun Hsu, et al.. (2014). Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(9). 1385–1392. 36 indexed citations
15.
Lee, Jih‐Hsiang, Kang‐Seo Park, Anna Teresa Alberobello, et al.. (2013). The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo. Clinical Cancer Research. 19(24). 6777–6786. 22 indexed citations
16.
Chen, Jin‐Qiu, Jih‐Hsiang Lee, Michelle A. Herrmann, et al.. (2013). Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 12(11). 2601–2613. 24 indexed citations
17.
Lee, Jih‐Hsiang, Elisa Giovannetti, Jin‐Hyeok Hwang, et al.. (2011). Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer. Clinical Cancer Research. 18(2). 524–533. 23 indexed citations
18.
Lee, Jih‐Hsiang, Johannes Voortman, Anne‐Marie C. Dingemans, et al.. (2011). MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer. PLoS ONE. 6(6). e21300–e21300. 66 indexed citations
19.
Lee, Jih‐Hsiang, Chong‐Jen Yu, Kuan‐Yu Chen, et al.. (2010). Pemetrexed for Heavily Pretreated Patients With Advanced Non-small Cell Lung Cancer. Journal of the Formosan Medical Association. 109(5). 338–344. 5 indexed citations
20.
Wu, Shang‐Gin, James Chih‐Hsin Yang, Chong‐Jen Yu, et al.. (2010). Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer. 72(3). 333–339. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Baglivo Breakdown of academic impact, for papers by Shinnosuke Ikemura Breakdown of academic impact, for papers by Assunta Sgambato Breakdown of academic impact, for papers by Ken Uchibori Breakdown of academic impact, for papers by Giuseppina Rosaria Rita Ricciardi Breakdown of academic impact, for papers by Pietro De Placido Breakdown of academic impact, for papers by Toshio Fujino Breakdown of academic impact, for papers by Naixin Liang Breakdown of academic impact, for papers by Akihiko Miyanaga
Rankless by CCL
2026